Abdelrahman Saqr

Abdelrahman Saqr

Auto-generated profile, based on publicly available information

Abdelrahman Saqr

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ASAbdelrahman Saqr
Abdelrahman Saqr
BCBrooke Carlson
Brooke Carlson
Christopher StaleyChristopher Staley
Christopher Staley
ARArmin Rashidi
Armin Rashidi
MAMahmoud Al-Kofahi
Mahmoud Al-Kofahi
PJPamala A. Jacobson
Pamala A. Jacobson
Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplantation (HCT). MMF has a narrow therapeutic index, and blood concentrations of mycophenolic acid (MPA), the active component of MMF, are highly variable. Low MPA concentrations are associated with the risk of graft-versus-host disease (GVHD), whereas high concentrations are associated with toxicity. Reasons for variability are not well known and may include the presence of β-glucuronidase-producing bacteria in the gastrointestinal tract, which enhance MPA enterohepatic recirculation (EHR) by transforming MPA metabolites formed in the liver back to MPA. This study was conducted to determine whether individuals with high MPA EHR have a greater abundance of β-glucuronidase-producing bacteria in their stool and higher MPA concentrations compared with those with low EHR. We conducted a pharmacomicrobiomics study in 20 adult HCT recipients receiving a myeloablative or reduced-intensity preparative regimen. Participants received MMF 1 g i.v. every 8 hours with tacrolimus. Intensive pharmacokinetic sampling of MMF was conducted before hospital discharge; total MPA, MPA glucuronide (MPAG), and acyl-glucuronide metabolite (acylMPAG) were measured. EHR was defined as the ratio of MPA area under the concentration-versus-time curve (AUC)4-8 to MPA AUC0-8. Differences in stool microbiome diversity and composition, determined by shotgun metagenomic sequencing, were compared above and below the median EHR (22%; range, 5% to 44%). The median EHR was 12% in the low EHR group and 29% in the high EHR group. MPA troughs, MPA AUC4-8, and acyl-glucuronide metabolite (acylMPAG) AUC4-8/AUC0-8 ratio were greater in the high EHR group compared with the low EHR group (1.53 μg/mL versus .28 μg/mL [P = .0001], 7.33 hour·μg/mL versus 1.79 hour·μg/mL [P = .0003], and .33 hour·μg/mL versus .24 hour·μg/mL [P = .0007], respectively). MPA AUC0-8 was greater in the high EHR group than in the low EHR group, and the difference trended toward significance (22.8 hour·μg/mL versus 15.3 hour·μg/mL; P = .06). Bacteroides vulgatus, Bacteroides stercoris, and Bacteroides thetaiotaomicron were 1.2- to 2.4-fold more abundant (P = .039, .024, and .046, respectively) in the high EHR group. MPA EHR was positively correlated with B. vulgatus (⍴ = .58; P ≤ .01) and B. thetaiotaomicron (⍴ = .46; P < .05) and negatively correlated with Blautia hydrogenotrophica (⍴ = -.53; P < .05). Therapeutic MPA troughs were achieved in 80% of patients in the high EHR group but in no patients in the low EHR group. There was a trend toward differences in MPA AUC0-8 and MPA concentration at steady-state (μg/mL) between the high EHR group versus the low EHR group (P = .06). MPA EHR was variable. Patients with high MPA EHR had greater abundance of Bacteroides species in stool and higher MPA exposure compared with patients with low MPA EHR. Therefore, Bacteroides may be protective against poor outcomes, such as graft-versus-host disease, in some patients but may increase the risk of MPA adverse effects in others. These data need to be confirmed and studied after oral MMF therapy.

14 June 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ASAbdelrahman Saqr
Abdelrahman Saqr
SCShen Cheng
Shen Cheng
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
Christopher StaleyChristopher Staley
Christopher Staley
PJPamala A. Jacobson
Pamala A. Jacobson
Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF). MPA undergoes glucuronidation to form MPA glucuronide (MPAG) which is deglucuronidated by bacterial β‐glucuronidases and reformed as MPA through enterohepatic circulation (EHC). We studied the stool microbiome effect on the pharmacokinetics of MPA, its metabolites, and EHC in hematopoietic cell transplant (HCT) recipients using a semi‐mechanistic population pharmacokinetic model. Microbiome communities were identified using correlation network analysis, and their impact on pharmacokinetics was assessed using full fixed‐effects modeling. Simulations were then conducted to evaluate MMF dosing regimens and to assess the impact of community abundance on EHC and MPA therapeutic target achievement. High abundance of Bacteroides uniformis ‐dominant and Bacteroides vulgatus ‐dominant communities was associated with higher EHC and an increase in MPA exposure. Low abundance of these communities was associated with a 52–80% and 4–83% lower EHC and MPA exposure, respectively. Simulations showed 70% of individuals with low abundance of these communities achieved the therapeutic target at the typical HCT MMF dose of 1,000 mg Q8 hours IV; however, ≥ 95% were within the therapeutic target at 1,250 mg Q8 hours or 1,750 mg Q12 hours. EHC accounted for 34% of the MPA area under the curve. Elimination of EHC reduced troughs by 100%. This work quantifies the microbiome’s effect on pharmacokinetics, paving the way for future microbiome‐informed dosing to optimize therapeutic target attainment.

12 July 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
ASAbdelrahman Saqr
Abdelrahman Saqr
MAMahmoud Al‐Kofahi
Mahmoud Al‐Kofahi
MMMoataz Mohamed
Moataz Mohamed
CDCasey Dorr
Casey Dorr
RRRory P. Remmel
Rory P. Remmel
PJPamala A. Jacobson
Pamala A. Jacobson
Aims: Tacrolimus, metabolized by CYP3A4 and CYP3A5 enzymes, is susceptible to drug–drug interactions (DDI). Steroids induce CYP3A genes to increase tacrolimus clearance, but the effect is variable. We hypothesized that the extent of the steroid–tacrolimus DDI differs by CYP3A4/5 genotypes.Methods: Kidney transplant recipients (n = 2462) were classified by the number of loss of function alleles (LOF) (CYP3A5*3, *6 and *7 and CYP3A4*22) and steroid use at each tacrolimus trough in the first 6 months post‐transplant. A population pharmacokinetic analysis was performed by nonlinear mixed‐effect modelling (NONMEM) and stepwise covariate modelling to define significant covariates affecting tacrolimus clearance. A stochastic simulation was performed and translated into a Shiny application with the mrgsolve and Shiny packages in R.Results: Steroids were associated with modestly higher (3%–11.8%) tacrolimus clearance. Patients with 0‐LOF alleles receiving steroids showed the greatest increase (11.8%) in clearance compared to no steroids, whereas those with 2‐LOFs had a negligible increase (2.6%) in the presence of steroids. Steroid use increased tacrolimus clearance by 5% and 10.3% in patients with 1‐LOF and 3/4‐LOFs, respectively.Conclusions: Steroids increase the clearance of tacrolimus but vary slightly by CYP3A genotype. This is important in individuals of African ancestry who are more likely to carry no LOF alleles, may more commonly receive steroid treatment, and will need higher tacrolimus doses.

6 February 2026 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
MMMoataz E. Mohamed
Moataz E. Mohamed
ASAbdelrahman Saqr
Abdelrahman Saqr
GOGuillaume Onyeaghala
Guillaume Onyeaghala
RRRory P. Remmel
Rory P. Remmel
Christopher StaleyChristopher Staley
Christopher Staley
PJPamala A. Jacobson
Pamala A. Jacobson
Background Mycophenolic acid (MPA) has complex pharmacokinetics in part due to enterohepatic recirculation (EHR). A deeper understanding of MPA pharmacokinetics and specifically how EHR and patterns of EHR affect exposure will improve immunosuppression outcomes. This study provides a contemporary and comprehensive assessment of MPA and metabolites in the blood and urine with a focus on EHR characteristics. Methods Kidney transplant recipients (n = 84) receiving mycophenolate mofetil (MMF) and tacrolimus underwent an intensive MPA pharmacokinetic assessment. Pharmacokinetics of MPA and its metabolites, EHR%, and number of secondary peaks were determined. The associations between EHR, the number of secondary peaks, and achievement of MPA therapeutic range were studied. MMF dose proportionality with MPA exposure was evaluated. Results MPA exhibited high pharmacokinetic variability, with 5.5-fold differences in AUC0–12, 18.4-fold differences in trough concentrations, and a 3.4-fold difference in EHR%. Median MPA EHR% was 40.5%. There were no significant associations between EHR% and MPA AUC0–12 or trough. MPA AUC0–12 and trough were significantly associated with the number of MPA secondary peaks (0, 1, or ≥ 2 peaks). Participants without secondary peaks showed the highest percentage of subtherapeutic MPA AUC0–12 and troughs, while participants with ≥ 2 peaks were more likely to be supratherapeutic. Conclusions There was no association between the EHR% and MPA AUC0–12 or trough. We identified three distinct patterns of MPA secondary peaks (0, 1, or ≥ 2 peaks), which were significantly associated with MPA AUC0–12 and trough. Studies to evaluate the relationship of MPA EHR measures and clinical outcomes are needed. Trial Registry Clinical Trial Notation: clinicaltrials.gov, NCT04953715.

23 August 2024 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
MMMoataz E. Mohamed
Moataz E. Mohamed
BGBin Guo
Bin Guo
BWBaolin Wu
Baolin Wu
DSDavid P. Schladt
David P. Schladt
AMAmutha Muthusamy
Amutha Muthusamy
BKBertram L. Kasiske
Bertram L. Kasiske

28 October 2026 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
ASAbdelrahman Saqr
Abdelrahman Saqr
MMMoataz E. Mohamed
Moataz E. Mohamed
Christopher StaleyChristopher Staley
Christopher Staley
GOGuillaume Onyeaghala
Guillaume Onyeaghala
DVDuy Vo
Duy Vo
PJPamala A. Jacobson
Pamala A. Jacobson